https://www.selleckchem.com/pr....oducts/pexidartinib-
und. Indirect treatment comparison showed no statistically significantdifferences in reduction of ≥ 50% migraine days/month betweenerenumab, fremanezumab and eptinezumab. Probable clinical equivalencewas found between these drugs in terms of efficacy and safety,therefore they could be considered equivalent therapeutic alternatives inchronic migraine. Indirect treatment comparison showed no statistically significant differences in reduction of ≥ 50% migraine days/month between erenumab, fremanezumab and eptinezumab. Probable
Like
Comment
Share
